Impaired insulin-stimulated glycogen synthesis of skeletal muscle is among the most consistent pathophysiological characteristics of late-onset Type II diabetes and studies of glucose-tolerant first degree relatives of patients with late-onset Type II diabetes have shown that decreased insulin sensitivity in the whole body and impaired insulin-stimulated glycogen synthesis of skeletal muscle precede the onset of Type II diabetes [1] . The genetic basis of these findings, however, is mostly not known but genes encoding proteins, active in the continuously expanding network of interacting molecules constituting the insulin signalling pathways, are plausible candidates for insulin resistance and Type II diabetes [2] . Metabolic effects of insulin (glucose uptake and glycogen synthesis) Diabetologia (2001) 
IVS1±96 A®G (allelic frequency 0.22, 95 % CI: 0.12±0.32), IVS3 + 99 C®T (0.01, CI: 0±0.03), IVS7±3 TT®T (0.10, CI: 0.03±0.18) and IVS8 + 32 G®T (0.35, CI: 0.23±0.47). The IVS8 + 32 G®T polymorphism was used as a bi-allelic marker for the PTEN locus and examined in 379 patients with Type II diabetes and in 224 control subjects with normal glucose tolerance. The IVS8 + 32 G®T polymorphism in the PTEN was not associated with Type II diabetes and it did not have any effect on body-mass index, blood pressure, HOMA insulin resistance index, or concentrations of plasma glucose, serum insulin or serum C peptide obtained during an oral glucose tolerance test (OGTT). Conlusion/interpretation. Variability in the PTEN is not a common cause of Type II diabetes in the Danish Caucasian population. [Diabetologia (2001) 44: 237± 240] Keywords PTEN, mutation, Type II diabetes mellitus, SSCP, RFLP.
are most likely mediated through the IR/IRS/PI 3 K signalling cassette and, hypothetically, abnormalities caused by genetic variabilities in these proteins might impair signalling and present as decreased insulinstimulated glucose uptake and glycogen synthesis [2] .
Recently, the protein phosphatase PTEN (also known as MMAC or TEP1) [3] has been introduced into the insulin signalling cassette as a lipid phosphatase that negatively regulates the concentration of intracellular phosphatidyl-inositol-(3, 4, 5)-trisphosphate generated in response to the activation of phosphoinositide 3-kinase (PI 3 K) [4] , preventing the downstream phosphatidylinositol (3, 4, 5)-trisphosphate (PIP 3 )-dependent activation of protein kinase B (PKB). Activation of the PI 3 K and PKB is an essential step in the insulin-stimulated glucose uptake and glycogen synthesis [2] , and recent studies of the regulation of PI 3 K and PKB isoforms in insulin-sensitive liver, muscle and adipose tissues in the obese Zucker rat model of insulin resistance suggest that PTEN is a potential candidate for regulating the signal transduction between PI 3 K and PKB [5] . This has been further investigated in the db/db insulin-resistant mice where inhibition of PTEN expression by the use of antisense technology improves insulin resistance and reverses hyperglycaemia [6] . As a modulator of insulin sensitivity, we considered PTEN a potential candidate gene for the development of insulin resistance and Type II diabetes. To test this hypothesis we carried out a mutational analysis of coding regions including exon and intron boundaries of the PTEN in 62 patients with Type II diabetes.
Materials and methods
Subjects. All patients with Type II diabetes were recruited at the outpatient clinic at Steno Diabetes Center, Copenhagen, and glucose-tolerant control subjects were traced through the Danish Central Personal Register. Type II diabetes was diagnosed according to the 1985 World Health Organisation (WHO) criteria and all the patients tested negative for anti-GAD antibodies. Before participation, the purpose and risk of the study were explained, and informed consent was obtained from all the participants. The protocol was approved by the ethics committee of Copenhagen and was in accordance with the Helsinki declaration II.
For primary mutation analysis DNA was isolated from leukocytes [8] ; age of clinical onset of diabetes, 55 5 years). Of the patients 28 % were diet treated, 58 % were treated with sulphonylurea or biguanide or both, and 14 % were treated with insulin. The characteristics of 224 matched unrelated glucose-tolerant control subjects are shown (Table 2 ).
Genetic analyses. Mutation analysis of the PTEN was done by polymerase-chain-reaction single-stranded-conformationpolymorphism (PCR-SSCP) and heteroduplex analysis using two different experimental conditions [8] . The PTEN was amplified in 10 segments (225±310 bp) on 100 ng of genomic DNA [8] . Individual PCR conditions and primers, located in intronic sequences to avoid amplification of the PTEN pseudogene Y PTEN, were designed from the genomic sequence (Acc. No. AF000726-AF000 734). For PCR amplification we used sense (a) 5'±3'/antisense (b) 5'±3' primers for each segment (intron) followed by an indication of the specific annealing temperatures and Mg 2+ concentrations (temp/Mg The SSCP variants were sequenced using Thermo Sequenase (Amersham, Cleveland, Ohio, USA) as described [8] . Mutations occurring within intronic regions are named IVS, followed by the intron number and a plus/minus, indicating the position of either downstream or upstream from the corresponding exon, and the given nucleotide changes. Genotyping of the G®T variant in position IVS8 + 32 was done by PCR amplification of segment 8 using primers 8 a, 8 b and restriction fragment length polymorphism (RFLP) using HphI restriction enzyme. The fragments were separated on a 3 % agarose gel and visualised by staining with ethidium bromide.
Biochemical assays. HbA 1 c , plasma glucose, serum insulin, and serum C peptide were analysed as described previously [7] and the HOMA insulin resistance index was calculated as the product of fasting plasma glucose and fasting serum insulin, leaving out the 22.5 constant.
Statistical analysis. Chi-squared and Fishers exact test as implemented in AssoTest ver. 04 a (Steno Diabetes Center, Dept. 521, Copenhagen, Denmark) was applied to test for any significant differences in allele frequencies. Normal distribution of the residuals were visually verified and data were logarithmically transformed if necessary. Serum insulin and serum C peptide concentrations were logarithmically transformed at all times. Statistical Package of Social Science (SPSS) for Windows, version 9.0 was used for analysis applying a generalized linear model. The analyses included age, BMI and sex as covariates. For the analysis of 30 min, 60 min, and 120 min concentrations of circulating insulin and C peptide, the corresponding fasting concentrations were also included as covariate in the model to account for differences in basal concentrations among subjects. A p-value of less than 0.05 was considered statistically significant. Data in text and table are given as means (SD).
Results
By applying PCR-SSCP-heteroduplex analysis and direct sequencing of the gene encoding the PTEN protein in patients with insulin-resistant Type II diabetes, we identified no coding region variants, but four intronic polymorphisms: IVS1±96 A®G (allelic frequency 0.22, 95 % CI: 0.12±0.32), IVS3 + 99 C®T (0.01, CI: 0±0.03), IVS7±3 TT®T (0.10, CI: 0.03±0.18) and IVS8 + 32 G®T (0.35, CI: 0.23±0.47). The IVS7±3 TT®T is a deletion of the last T in a stretch of fifteen T's in the 3'-end of intron 7 and does not predict any changes in the splice acceptor consensus sequence. The IVS8 + 32 G®T variant was used as a bi-allelic marker for the PTEN locus as a potential diabetes-associated chromosomal locus in an association study comprising 379 patients with Type II diabetes and 224 normal glucose-tolerant control subjects, matched for age, BMI and gender. The examined IVS8 + 32 G®T variant was in Hardy-Weinberg equilibrium. The allelic frequency of the IVS8 + 32 G®T variant was not different between patients with Type II diabetes (allelic frequency 0.35, CI: 0.30±0.40) and the control subjects (allelic frequency 0.35, CI: 0.28±0.42). The IVS8 + 32 G®T variant did not have any impact on insulin resistance (HOMA index) and it did not interact with obesity (BMI) in either the Type II diabetic subjects or the glucose-tolerant control subjects when a PTEN*BMI interaction term was included in the regression analy- [9] . In this study we failed to detect genetic variants that would predict changes in the PTEN protein either in the form of amino acid substitutions or alternative splicing. Furthermore, we found no evidence for an association of the PTEN locus with Type II diabetes or relevant quantitative metabolic traits (insulin-resistant phenotypes) when the IVS8 + 32 G®T variant was applied as a bi-allelic marker. We therefore conclude that variability in the coding region of the PTEN is not likely to be a common cause of Type II diabetes and insulin-resistant phenotypes in Danish Caucasian subjects.
